Prior Authorization Approval Criteria

Celebrex (celecoxib)

Generic name: Celecoxib
Brand name: Celebrex
Medication class: COX-II inhibitor, NSAID
FDA-approved uses: Ankylosing spondylitis, Juvenile rheumatoid arthritis, Osteoarthritis Acute Pain, Primary dysmenorrhea, Rheumatoid arthritis
Usual dose range: Osteoarthritis: 100 mg b.i.d. or 200 mg q.d.
Rheumatoid arthritis: 200 mg b.i.d.
Duration of therapy: Indefinite

Criteria for use (bullet points below are all inclusive unless otherwise noted):
- The indicated diagnosis (including any applicable labs and/or tests) and medication usage must be supported by documentation from the patient’s medical records.
- Diagnosed with rheumatoid arthritis, osteoarthritis, chronic pain, acute pain, or primary dysmenorrhea.
- At least one of the following
  - 70 years or older
  - Failed/intolerant to three NSAIDs
  - Documented history of GI bleed
  - Documented history of peptic ulcer disease
  - Chronic corticosteroid use
  - Documented history of NSAID-induced gastritis
  - Predisposition to GI bleed
  - Anticoagulant use (exercise caution due to ulcer potential).

Not approved if:
- Patient has renal disease
  - OR
- Patient with moderate to severe hepatic failure/disease

Drug interactions:
Celecoxib is metabolized by the CP450 and 2C9 enzymes; therefore, use with the following medications could cause a drug interaction:
- Amiodarone
- Fluconazole
- Omeprazole
- Zafirlukast

Other Issues:
- Lithium levels could be increased
- Celecoxib could impair the antihypertensive actions of ACE inhibitors and furosemide
- Pregnancy category C

The criteria listed above applies to Fallon Health Plan and its subsidiaries.
FCHP Pharmacy and Therapeutics Committee approval: ________________________________

Date: ______________________

Adopted: 11/15/04
Revised 12/28/12, 6/8/16, 9/14/16
Effective: 11/19/16